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NeurodegenerationAmyotrophic lateral sclerosis (ALS) is an adult onset neurodegenerative disease pathologically characterized
by themassive loss of motor neurons in the spinal cord, brain stem and cerebral cortex. There is a consensus in
the ﬁeld that ALS is a multifactorial pathology and a number of possible mechanisms have been suggested.
Among the proposed hypothesis, glutamate toxicity has been one of the most investigated. Alpha-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor mediated cell death and impairment of
the glutamate-transport system have been suggested to play a central role in the glutamate-mediated
motor neuron degeneration. In this context, the role played by the N-methyl-D-aspartate (NMDA) receptor
has received considerable less attention notwithstanding its high Ca2+ permeability, expression inmotor neu-
rons and its importance in excitotoxicity. This review overviews the critical role of NMDA-mediated toxicity in
ALS, with a particular emphasis on the endogenous modulators of the NMDAR.
© 2012 Elsevier B.V. All rights reserved.1. Glutamate and the NMDA receptor complex
Glutamate is the major excitatory neurotransmitter in the Central
Nervous System (CNS). As well as functioning as a neurotransmitter
[1], increased extracellular glutamate concentrations can be toxic to
neurons [2,3]. Upon its release at the synaptic cleft glutamate activates
two families of receptors: the ligand-gated ion channels (ionotropic)
[4] and the G protein-coupled receptors (metabotropic) [5]. Its action
is quickly terminated by speciﬁc and effective reuptake systems locat-
ed at the synapse and in the astrocytes surrounding the synapse [6].
Within the astrocytes, glutamate is converted in glutamine, which is
released, reuptaken by neurons and converted back to glutamate,
then packed by the vesicular glutamate transporters into synaptic ves-
icles, ready to be released (Fig. 1) [7]. Glutamate receptors are impor-
tant in neuronal plasticity, development and in neurodegeneration
[8].
Glutamatergic ionotropic receptors, include the one responsive to
N-methyl-D-aspartic acid (NMDAR), the alpha-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPAR) and the Kainate receptor
[9]. These receptors are tetrameric or pentameric structures. The sub-
units that comprise these receptors are speciﬁc for each of the three
families [10], and determines their biophysical and pharmacological
properties.
Glutamate excitotoxicity, a term created by Olney [11], indicates
the neuronal dysfunction and degeneration caused by excessive extra-
cellular glutamate, a process resulting in neuronal death by necrosis ornit, Experimental Neurology,
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l rights reserved.apoptosis depending on the severity of the insult [12]. The central
dogma of excitotoxicity has been for many years that glutamate-
induced cell damage and death are the result of the activation of glu-
tamate receptors and that these effects can be blocked by the use of
competitive or non-competitive glutamate receptor inhibitors [13].
Throughout the years particular importance has been given to the
fact that glutamate, through the activation of its receptors, can trigger
large increases in free Ca2+ levels into neurons [14,15] and it is gen-
erally accepted that the NMDAR subtypes play a major role in the pro-
cess, mainly because of their high Ca2+ permeability. NMDAR is unlike
the other subtypes of glutamate receptors in three important aspects:
1) it requires the presence of a co-agonist (glycine/D-serine) with the
agonist (L-glutamate) to reach maximum activation; 2) its perme-
ability is reduced at hyperpolarized membrane potentials, due to a
voltage-dependent Mg2+ block; 3) its Ca2+ permeability is higher
compared to other glutamate receptors [16–18].
The NMDAR and AMPAR, each with distinct physiological proper-
ties, often coexist at the same synapse. Normally, at restingmembrane
potential, a weak synaptic stimulation only activates AMPAR, while
NMDAR are substantially not responding, because of their Mg2+
block. However, when the strength or the frequency of the afferent
input is adequate, the AMPA-mediated depolarization removes the
Mg2+ block from NMDA receptors, thus allowing large amounts of
Ca2+ to ﬂux into the cell. Ca2+ acts as an important secondmessenger,
activating several intracellular signaling cascades. Intracellular Ca2+
accumulation, resulting in glutamate-induced neurotoxicity [19,20],
originates from the extracellular milieu and, in large proportion,
from intracellular Ca2+ pools following NMDAR activation [21,22]. It
is also assumed that the increase in intracellular Ca2+ causes en-
hanced metabolic stress on mitochondria that leads to excessive oxida-
tive phosphorylation and increased production of reactive oxygen
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Fig. 1. Illustration of the glutamatergic synapse. Glutamate released from the pre-synaptic neuron in a voltage dependent manner, activates the glutamate receptors present on pre-
and postsynaptic neurons as well as on glial cells. These include ionotropic receptors, AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid), NMDA (N-methyl-D-
aspartate) and kainate receptors, and metabotropic receptors (mGluRs). Glutamate effects are determined by the receptor subtypes, synaptic localization and by the interaction
with scaffolding and signaling proteins in the postsynaptic density (PSD). Glutamate receptor activation results not only in rapid ionotropic effects, but also in long-term synaptic
plasticity. Glutamate is cleared from the synaptic cleft by the excitatory amino-acid transporters present predominantly on glial cells (GLAST; GLT-1), but it is also active on neurons
(EAAC1). Within glial cells glutamate is converted to glutamine by the glutamine synthetase. Glutamine is then released from the astrocyte, transported back into the presynaptic
neuron by the glutamine transporter (GlnT) and converted to glutamate by the glutaminase. Glutamate is packaged into presynaptic vesicles by the vesicular glutamate transporter
(VGluT), and is ready to be released.
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excitotoxicity is excitotoxic dendritic injury (termed dendrotoxicity)
[23], characterized by the formation of focal swelling (varicosities/
beads) along the dendritic arbour [24] and the resulting spine loss
[25,26]. Excitotoxicity has been linked to several pathological states of
the nervous system such as seizures, ischemia, anoxia, inﬂammation,
and neurodegenerative disorders [2,27–29].
Fig. 2A is a schematic representation of the NMDAR complex, its
binding sites, and its interaction with components of the post-
synaptic density (PSD) and the cytoskeleton. NMDARs are made of
four subunits forming a central canal selective for cations (Na+, K+
and Ca2+). These subunits have similar structural characteristics as
other members of the glutamate ionotropic receptor family, an extra-
cellular N-terminus domain, an intracellular C-terminus domain and a
re-entrant transmembrane domain [1]. L-glutamate is not the only ag-
onist for the NMDAR (Fig. 2B). Glycine and D-serine are co-agonists of
the NMDAR, and both transmitters must bind in order for the receptor
to function. Three NMDAR subunit families have been identiﬁed:
GluN1, GluN2 and GluN3 [30]. The NMDARs are heteromers consisting
of two essential GluN1 subunits, four isoforms of GluN2, and two
isoforms of GluN3 subunits. Eight splice-variant isoforms of GluN1
(GluN1a to 4a and GluN1b to 4b), four isoforms of GluN2 (GluN2A-D),
and two isoforms of GluN3 (GluN3A-B) have been identiﬁed. The
combinations of various heterotetrameric subunits assemblies give
rise to amultiplicity of functionally distinct NMDAR [30], usually asso-
ciating two GluN1 and two GluN2 subunits. The NMDAR incorporating
the GluN3 are believed to form complexes either in diheteromeric(GluN1/GluN3) and/or triheteromeric (GluN1/GluN2/GluN3) assem-
blies [1].
The GluN1 subunit is obligatory in the shaping of the receptor and
is ubiquitously expressed in the embryonic and adult CNS, with devel-
opmental and regional variations depending on the type of GluN1
isoform [31]. GluN2 subunits have different expression patterns in
both time and space [32] with GluN2B and 2D being highly expressed
in the embryonic brain, whereas the expression of GluN2A gradu-
ally increases during development [33]. GluN2C appears after birth,
and in the adult it is restricted to the cerebellum. Functionally
the developmental switch of the GluN2 subunit-expression is
manifested as changes in the receptor kinetics and in the sensitivity
to the modulation of NMDAR-mediated synaptic currents [34,35].
The binding sites for glutamate and glycine/D-serine are found on dif-
ferent subunits. Glycine and D-serine bind to the GluN1 subunit while
glutamate binds to the GluN2 subunit. This is one reason why both
subunit types are required to generate a fully functioning receptor.
The GluN2B subunit also possesses a binding site for polyamines, reg-
ulatory molecules that allosterically modulate the NMDA receptor.
GluN3 has a distinctive expression proﬁle [36]. The GluN3A peaks
early after birth and then decreases in adulthood, while the GluN3B
expression is low in early life and increases to reach a maximum in
adult animals, thought to be restricted to the brain stem and spinal
cord, is, instead, ubiquitous [37]. NMDARs have different subcellular
localizations (postsynaptic, perisynaptic, extrasynaptic as well as pre-
synaptic) and the subunit composition may vary according to their
localization [38,39].
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Fig. 2. (A) Schematic diagram representing the NMDAR complex with the agonist and co-agonists binding sites, the voltage-dependent Mg2+ block, the phencyclidine (PCP) site. A
schematic topology of the components of the post-synaptic density (PSD) network of scaffolding (Shank) and signaling (CaMKII, SynGAP, Ras, Citron, Rho, nNOS) proteins associ-
ated with the receptor is also represented. Note that the exact orientation of the MAGUK (PSD95, SAP102) in the PSD is not known and would be affected by their interaction with
the NMDAR and other proteins of the PSD network. For a more complete description of the organization of the NMDAR at the synapse see Petralia et al. [39]. (B) Molecular structure
of NMDAR agonists and co-agonists.
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is modulated by several small endogenous molecules such as H+ and
Zn2+, acting as allosteric modulators. NMDAR has a unique role in
synaptic integrations and as an activator of intracellular signalling cas-
cades, and the different subunits compositions confer to each receptor
subtype speciﬁc biophysical and pharmacological properties.
The NMDAR have a high Ca2+ permeability and slow activation/
deactivation kinetics [33], thereby playing an important role in
excitotoxicity. The Ca2+ entering via over-activated NMDARs results
in higher cell death compared to the Ca2+ entering through non-
NMDA glutamate receptors or voltage-gated Ca2+ channels [21,39].
The NMDA-mediated excitotoxicity occurs through different Ca2+
signalling pathways involving a range of Ca2+ signalling molecules
[40,41] and the interaction with the membrane-associated guanylate
kinase (MAGUK) family of scaffolding proteins [42]. NMDAR activa-
tion stimulates nitric oxide syntethase (NOS) activity which causes
NO production and the subsequent formation of peroxynitrite
(OONO−) resulting in neuronal damage [43], activation of the c-Jun
N-terminal Kinase (JNK) [44] and induction of the poly(ADP-ribose)
polymerase (PARP-1) as a mediator of excitotoxicity [45].
2. Amyotrophic lateral sclerosis and NMDAR expression in the
spinal cord
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease, characterized by muscle atrophy (amyotrophic), weakness,
and fasciculation indicative of a disease of the upper and lower
motor neurons (MNs). Lateral sclerosis refers to the hardness of the
spinal cord lateral columns in autopsy specimens, due to the massive
gliosis caused by the degeneration of the corticospinal tracts [46].
The antiglutamatergic drug Riluzole, despite the over 30 phase II and
phase III clinical trial [47,48], remains the only disease-modifyingdrug for the treatment of ALS. Riluzole controls neuronal hyper-
excitability by inhibiting the voltage-dependent sodium channels
[49,50] and by reducing glutamate release, uptake and glutamate re-
ceptor function [51,52].
ALS occurs in familial (10%, fALS) and sporadic (90%, sALS) forms
clinically indistinguishable. A growing number of ALS-causing genes
have been identiﬁed and are under investigation [53]. The ubiqui-
tously expressed enzyme Cu2+/Zn2+ superoxide dismutase was the
ﬁrst of such gene to be associated with ALS [54]. SOD1 mutations
are common in both fALS and sALS, and have been studied in the
most depth. Over 150 SOD1 mutations have been linked to fALS,
and are typically present in about 20% of such cases, as well as in up
to 7% of sALS cases [55]. Other genes associated with fALS include
alsin (ALS2) [56], senataxin (ALS4) [57], vesicle associated membrane
protein associated protein B(VAPB, ALS8) [58], angiogenin [59], a mu-
tation in the p150 subunit of dynactin (DCTN1) [60], as well as alter-
ations in the vascular endothelial growth factor (VEGF) gene [61].
Recently, genes such as TARDBP, FUS, and ANG (involved in RNA me-
tabolism) [62] have been identiﬁed as proven cases of both fALS and
sALS.
Transgenic animal models carrying mutant SOD1 (mSOD1) [63]
have been a valuable tool to study the pathological mechanisms un-
derlying the progressive degeneration of MNs. Moreover, the recently
developed transgenic mice expressing wild-type or mutant TDP-43
[63] should hopefully help us to further expand our understanding
of the disease pathophysiology.
Glutamate has been linked to the pathogenesis of ALS since the
seminal work of Plaitakis and Caroscio [64] and Rothstein et al. [65].
These authors described a signiﬁcant increase of both plasma and ce-
rebrospinal ﬂuid (CSF) glutamate levels in ALS patients. Following
these ﬁrst observations in 1992 Rothstein et al. [66] have then de-
scribed a marked decrease in the maximal velocity of transport for
Table 1
Predominant NMDAR subunits localization in themouse spinal cord during development.
NMDAR subunits Spinal cord laminae Stage of development
GluN1 VIII–IX After birth
GluN2A I, III and IV Embryos stage
GluN2B I, II, IX After birth
GluN2C I, II After birth
GluN2D undetectable
GluN3A I, II III–VI Embryos stage
GluN3B I–II and VIII–IX After birth
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tions from ALS patients. The following year Couratier and co-workers
[67], reported toxic effects of CSF obtained from ALS patients when ex-
posed to rat cultured neurons. They also assessed neuroprotective
effects of the AMPAR antagonist CNQX, while two NMDAR antagonists
(MK801 and AP7) were not found to be neuroprotective. These obser-
vations encouraged the search for a glutamatergic/excitotoxic mecha-
nism in ALS pathology (Fig. 3) that was initially narrowed down to
glutamate transporters [68] and Ca2+ permeable AMPAR [69–71]. The
role played by NMDARs, although investigated since the early nineties
[72], has been somehow neglected and received less attention.
The pattern of expression of NMDAR subunits in the spinal cord
changes during development (Table 1). In 1992 Kalb et al. [73] used
quantitative receptor autoradiography to show that NMDAR binding
decreases during development and that it is restricted to the sub-
stantia gelatinosa, with a progressive loss of its presence in other
areas, including the ventral horn. These ﬁndings where then function-
ally conﬁrmed by Hori et al. [74] who reported a substantial lack of
sensitivity to bath application of NMDA in adult mouse cervical spinal
cord. However, using an antigen-unmasking method, Todd and
co-workers [75] provided the ﬁrst anatomical evidence that NMDARs
are present at synapses in the ventral horn. The authors revealed a
synaptic distribution of GluN1 throughout the grey matter, and
GluN2A was found to be concentrated in laminae III–IV, while
GluN2B is present in laminae I–II, but is also expressed in lamina IX.
GluN1 transcripts (considering all the isoforms) have a robust expres-
sion after birth throughout the spinal cord, and they decrease in adult-
hood, eventually showing a higher expression in the ventral horn. At
birth the GluN2A transcript is highly expressed in the ventral horn,
while lower levels are present in other areas of the gray matter of
the whole spinal cord. In adult rat preparations GluN2A expression isSynaptic
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to neuronal plasticity. The action of the neurotransmitter is ultimately terminated by the i
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the glial glutamate transporter GLAST/GLT1 determines a pathological increase in the
over-stimulation of the glutamate receptors on the postsynaptic neurons with a consequen
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(ROS/RNS) concentrations. The occurrence of all these events leads to cell death.very low, while GluN2B and GluN2C transcripts have a similar expres-
sion that is moderate after birth and barely visible in adult. GluN2D
signal is, on the contrary, undetectable [76] although GluN2D mRNA
has been detected in the lumbar spinal cord ventral horn of adult fe-
male rat [77]. Both isoforms of GluN3 are present in the spinal cord.
GluN3A is highly expressed, while in MNs there is a reciprocal expres-
sion between GluN3B and GluN2A. Decreased levels of GluN2A mRNA
are balanced by an increase of the GluN3B transcript from P14 to
adulthood [78]. Interestingly, the GluN3B subunit expression is re-
stricted to the somatic MNs in the cranial nerve nuclei (i.e. trigeminal
motor and facial nuclei) and in the spinal anterior horn [79], which
degenerate in ALS. Remarkably, a lower expression of the GluN3B
subunit has been observed in a distinct group of MNs (Onuf's nucleus
and oculomotor nuclei) that do not degenerate in ALS. Conversely the
GluN3A subunit, in early post-natal life, has been linked to the inhibi-
tion of glutamatergic synaptic transmission, thus hampering the pre-
mature development of synapse size, and strength during early
development [80]. Furthermore, the inclusion of GluN3A in NMDARs
reduces currents, lowers calcium permeability, and lowers the sen-
sitivity of NMDARs to the magnesium block. Thus, a misbalanceER stress
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t cellular excitotoxicity on top of concurrent factors such as mitochondrial failure and
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contribute to the malfunctioning of MNs in adulthood.
InMNs, functional NMDARs becomeoperative in the prenatal period
[81,82], then they decline during the second postnatal week due to the
Mg2+ blockade [83]. NMDARs have an important role in the generation
of rhythmic bursting in the spinal cord [84], mediate the slow com-
ponent of MN excitatory postsynaptic currents [85], and the activity-
dependent development of MNs require NMDARs activation [81].
Palecek et al. [86] proposed that at least two types of NMDARs exist in
spinal cord MNs, high-conductance and low conductance receptors.
Their data suggest that the high-conductance NMDARs contain GluN1
and GluN2B subunits, and a subunit inﬂuencing single-channel conduc-
tance and afﬁnity forMg2+, possibly GluN3A [87]. The low conductance
NMDAR, on the other hand, corresponds to those channels produced by
recombinant expression of GluN1/GluN2C or GluN1/GluN2D subunits.
In the adult mammalian MNs the role of NMDARs remain elusive.
However this year, two reports have established the existence, in
adult MNs, of NMDA-driven currents. Manuel et al. [88], used an in
vitro sacral cord preparation, to demonstrate that in the adult rodent
spinal cord the MNs innervating the muscles of the tail are sensitive
to a bath application of NMDA. Enriquez Denton et al. [89] looked at
the role of the persistent inward currents in cat respiratory MNs
(phrenic inspiratory and thoracic expiratory) and concluded that the
voltage-dependent ampliﬁcation of synaptic excitation in phrenic
MNs is mainly the result of NMDA channel modulation, since it is
markedly suppressed under a NMDAR block.
Similarly, studies of spinal neuronal excitability in ALS thus far
have been restricted to cell culture and neonates, and have quite ex-
clusively looked at AMPAR-mediated currents and neuronal hyper-
excitability mainly mediated by Na+ currents. However, Heckman
and co-workers [90] used mSOD1 mice to test whether NMDARs
contribute to the increased bursting activity generated by spinal in-
terneurons. Their results indicate that the NMDAR in spinal interneu-
rons is a potential source of over-excitation of MNs as the symptoms
develop. Although not directly studied on MNs their results indicate
the presence of a functional NMDAR in the adult spinal cord that sug-
gests signiﬁcant activation of interneurons by NMDA, yet they do not
exclude a role of NMDA acting directly on MNs. In a more recent work
Quinlan et al. [91] compared the development of MNs electrical prop-
erties in normal and mSOD1 from birth to 12 days of age. They
observed that most of the electrical properties in the mSOD1 MNs
showed an accelerated pace of maturation during this early develop-
mental period compared with the normal MNs. Thus, it is conceivable
to hypothesize that, similarly to the electrical properties, more global
changes in spinal networks are present, these changes could include
altered glutamatergic neurotransmission and altered functional prop-
erties of NMDARs.
3. NMDA-mediated excitotoxicity and MNs death
NMDAR-mediated neurotoxicity and subsequent overload of mito-
chondrial Ca2+ and ROS production has been shown to take place in
culturedMNs [69,92]. In chick embryo organotypic spinal cord culture
NMDA, similarly to glutamate and Kainate, triggers MN degeneration
[93]. NMDA/Ca2+-mediated excitotoxicity has been demonstrated in
the neuronal loss observed in spinal neurons obtained from hNFL+/+
mice, an ALS mouse model [94]. In this neuroﬁlament (NF) aggregate-
bearing MN model, NMDA mediated toxicity is due to sequestration
of nNOS on NF aggregates and failure of nNOS translocation to
NMDAR, thereby allowing unregulated calcium to ﬂux in response to
a glutamatergic challenge [95].
The over-activation of NMDAR results in mitochondrial membrane
depolarization and opening of the mitochondrial permeability transi-
tion pore (mPTP), reactive oxygen species (ROS) production and
caspase activation [96,97]. Mitochondria possess the ability to sequester
large quantities of Ca2+within theirmatrices resulting inmitochondrialdepolarization (i.e., reduction in the mitochondrial membrane poten-
tial, Δψm) [98]. Mitochondrial Ca2+ accumulation and the subsequent
release is a critical step in acute glutamate excitotoxicity [99,100], lead-
ing to failure to maintain intraneuronal Ca2+ concentrations. Compel-
ling evidence supports the fact that excessive Ca2+ inﬂux through
NMDARs targets mitochondria [101,102] which sets off death mecha-
nisms also recognized as excitotoxic in ALS-related MN death.
Mitochondria-mediated apoptosis has been linked to MN degeneration
[103,104] and the involvement of themPTPhas been shown as an active
player in the mechanisms of MN death in ALS [105]. Accordingly,
mPTP-driven glutamatergic excitotoxicity has been observed in spinal
glycinergic interneurons and MNs and has been related to ALS
neurodegeneration [106]. Strong and co-workers [94] have reported
that Ca2+-mediated excitotoxicity in NF aggregate-bearing MNs in
vitro is mostly NMDA dependent and requires caspase-3 activation.
The sequential activation of caspase-1 and -3 has been observed in
MNs and astrocytes bearing the mSOD1 forms G93A and G37R [107].
NMDAR excitotoxicity results in Ca2+ release from the endoplas-
mic reticulum (ER). The ER is an intracellular organelle responsible
for protein synthesis and protein post-translational correct “folding”.
In addition, the ER also serves as a Ca2+ store, contributing to the
cytosolic Ca2+ signalling cascade by releasing Ca2+ primarily through
ryanodine (RyR) and IP3 (IP3R) receptors [108]. These receptors have
a central role in cell survival, but they are also crucial in apoptotic cell
death [109]. Ruiz et al. [110] demonstrated that the NMDA-mediated
ER-stress could be attenuated with the application of RyR/IP3R inhib-
itors, giving evidence to the ER contribution to excitotoxicity. The up-
take and release of Ca2+ by the ER tend to maintain a balanced Ca2+
concentration between the ER and its surroundings, in particular
through the mitochondria Ca2+ buffering capacity [111]. The de-
rangement of this interplay can induce Ca2+ depletion from the intra-
cellular stores, accumulation of misfolded proteins and activation of
the unfolded protein response (UPR) [112]. The UPR is a signaling net-
work that regulates the response to ER stress to recover a proper ER
function, its failure results in cell death through apoptotic mecha-
nisms [113]. ER stress and UPR dysfunction intervene in the ALS-
mediated death. The aggregation-prone mSOD1 accumulates in the
ER triggering ER stress [114], while caspase-12, an ER stress-related
caspase is activated in the G93A mice [115]. Kanekura et al. [116]
predicted that the vesicle-associated membrane protein-associated
protein B (VAPB/ALS8), an autosomal-dominant ALS-causative gene
[58], is involved in the UPR signal. Recently, Prell et al. [117] provided
direct evidence of the activation of the UPR response in the NSC34
cells carrying the G93A mutation. Moreover, Tarabal et al. [118] dem-
onstrated that in chick embryos MN chronic NMDA treatment results
in protein aggregation and Ca2+ accumulation within the ER, and ac-
tivation of autophagy, linking NMDA-mediated excitotoxicity to ER
stress and MN death.
A peculiar characteristic of the NMDAR is that a range of endoge-
nous ligands can allosterically modulate its activity. Glycine/D-serine,
Zinc and polyamines have all been linked to ALS pathophysiology.
Here we review their modulation of NMDARs and their link to ALS.4. Glycine/D-serine
To be activated by glutamate the NMDAR needs a co-agonist that
occupies the asparagine residue (N598) located at the GluN1 subunit
[119]. The binding by the co-agonist is essential not just for NMDAR
activity, but also to increase the receptor afﬁnity for glutamate [120],
decrease its desensitization [121] and to promote receptor turnover
[122]. Glycine and D-serine are the two endogenous co-agonists that
modulate NMDAR function. Initially glycine was believed to be the
co-agonist of choice [123]. More recently D-serine has become the
physiological dominant co-agonist with an afﬁnity to the GluN1 bind-
ing site up to three fold higher than that of glycine [124,125] (Fig. 4;
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the extracellular milieu in response to an increase in Ca2+. In neurons, D-serine is synthesized from astrocytes-derived L-serine by SR. D-serine, a co-agonist with glutamate, can act
on synaptic, extrasynaptic and probably presynaptic NMDARs. D-serine is shuttled between neurons and glia by the neutral amino acid transporters present in astrocytes (ASCT or
similar) and in neurons (Asc-1 or similar). These transporters also function as a reversal uptake system and contribute to extracellular D-serine release. For a more detailed descrip-
tion of the serine pathway and shuttle system see Maya et al. [126], Wolosker [127] and Henneberger et al. [128].
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modulators.
Glycine is an abundant amino acid found throughout the brain
with a synaptic concentration tightly regulated by glycine trans-
porters. At NMDAR-expressing synapses, extracellular glycine concen-
trations are derived for the most part from astroglial cells and
clearance is mediated by a glycine transporter 1 (GlyT-1) [129] closely
associated with NMDARs [130]. GlyT-1 effectively maintains low,
subsaturating levels of glycine, as GlyT-1 blockers are capable of en-
hancing NMDAR activity [131]. High-afﬁnity glycine transport sys-
tems tightly regulate glycine access to the NMDAR sites [132] thus
keeping the glycine concentration near the NMDAR sufﬁciently low
to allow D-serine to be the major regulator of the NMDAR activity at
their binding site [133]. Indeed, when observingNMDA elicited neuro-
toxicity in organotypic hippocampal slices, the effect of endogenous
glycine could only be observed after simultaneous removal of endog-
enous D-serine and blockage of GlyT1 [125], despite the level of endog-
enous glycine being 10-fold higher than the D-serine concentration.
Glycine enhances glutamate release, through the activation of its
transporter, in spinal cord synaptosome preparations from SOD1G93A
mice [134]. Rodriguez-Ithurralde and co-workers [135] demonstrated
that glycine-evoked acethylcholinesterase release, from slices and
spinal ventral horn synaptosomes, leads to increased MN vulnerability
to excitotoxic stress. In this context, it is noteworthy that GluN1/
GluN3A-B NMDARs coassemble to form “excitatory glycine receptors”,
as they require glycine alone for activation, in the absence of glutamate
or NMDA [136,137]. It is conceivable that the selective expression of
these “excitatory glycine receptors” on ALS-affected somatic MNs (seethe “Amyotrophic Lateral Sclerosis and NMDAR expression in the spinal
cord.” section) could contribute to the increased MNs susceptibility to
excitotoxicity.
The modulation of the NMDAR by D-serine has received more and
more attention as a contributing factor to the glutamate excitotoxicity
in ALS. Sasabe et al. [138] found an age-related increase (from 9 to 21
weeks of age) of D-serine in the spinal cord of G93A mice. They also
observed its accumulation around vacuolated MNs at early disease
stages and in activated astrocytes and microglial cells at end stages.
They linked the increased levels of D-serine with an up-regulation of
the converting enzyme serine racemase (SR) in microglial cells and
demonstrated a D-serine enhanced NMDA toxicity via the activation
of the ERK1/2-/p38-mediated apoptotic pathway. Accordingly they
found increased levels of D-serine in the spinal cord of sporadic and
familial specimens of human ALS cases. These ﬁndings persuaded
them to propose a novel mechanism where neuronal excitotoxicity
is mediated by glia-derived D-serine and the resulting chronic activa-
tion of NMDARs, linking non-cell autonomous MN death, mSOD1 and
excitotoxicity, three established causes of ALS. [138]. These authors
(139) recently described a mice lacking D-amino acid oxidase (DAO)
activity, because of a natural point mutation (G181R), MN degenera-
tion of the lumbar ventral horn, including a reduction in number and
size of their somata. Furthermore, in aged mice, carrying the DAO
inactivation, they observed ubiquitin-positive aggregations in the
ventral horn, increased ubiquitin-immunoreactive smear in the im-
munoblotting of the spinal cord and axonal degeneration with muscle
atrophy. They also looked at DAO activity in the SOD1G93A mouse,
the most studied ALS animal model, and found that DAO activity
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cord and in the reactive astrocytes of the brainstem reticular forma-
tion [139]. As a consequence of DAO decreased activity they mea-
sured increased D-serine levels, and found that astrocytic down-
regulation of DAO gene expression is mediated by the NMDAR/ERK
pathway [139]. They conclude that DAO inactivation in the re-
ticulospinal tract was not caused simply by expression of the
SOD1G93A gene, but was affected by ALS pathophysiology. However,
reduced DAO activity may not represent all ALS cases since DAO activ-
ity is not suppressed in mTDP43 mice. Interestingly, a unique muta-
tion (R199WDAO) in the DAO gene segregates with the disease
[140]. Thus, the role of D-serine as a potential enhancer of MN excit-
ability through the NMDAR is of pathological relevance.
Furthermore, in vivo decrease or increase in D-serine levels
gives rise to contradictory results, according to the data shown by
Thompson et al. [141].These authors examined the role of D-serine in
the disease pathogenesis using two different approaches. They cross-
bred the G93A mice with the SR null mice (SR−/−). SR is the enzyme
that transforms L-serine into D-serine. Thus generating a G93A
mouse with a diminished or absent SR protein that exhibit signiﬁcant
early motor symptom onset but extended survival with a slow rate of
motor function and loss of body weight compared to the G93Amouse.
In a separate set of experiments they administered D-serine to G93A
mice from the onset of the symptoms until death, and observed a dra-
matic decrease in spinal cord D-serine (but a signiﬁcant increase in the
brain), early onset of motor symptoms, but with a signiﬁcantly slower
disease progression. In both cases lowering D-serine in the spinal cord
delays disease progression. Thus, although unable to affect disease
onset, the ability to positively interfere (delay) with the course of
the disease is of interest for the ALS pathophysiology.
5. Zinc
The role of Zinc (Zn2+) in ALS has been investigated since domi-
nant missense mutations in the antioxidant enzyme Cu/ZnSOD1
have been linked to 20-25% of all fALS cases [54]. Its role has been
considered essential in relation to SOD1 binding afﬁnity to the ion
that was discovered to be signiﬁcantly decreased in the mutant pro-
tein [142]. In 1999 Beckman and coworkers [143] reported that the
loss of Zn2+ from wild-type and mSOD1 was sufﬁcient to induce ap-
optotic cell death in cultured MNs. These data led them to conclude
that Zn2+-deﬁcient SOD participate in both sALS and fALS via a
NO-dependent oxidative mechanism.
Zn2+ has important functions as a neurotransmitter and recep-
tor modulator. Zn2+ is an essential trace element tightly bound to
Zn2+-dependent enzymes and other proteins (about 90%), while
approximately 10% is free or chelatable. Free Zn2+ is predominantly
packed in presynaptic vesicles and is, upon neuronal excitation, re-
leased into the synaptic cleft. The primary action of Zn2+ appears to
be the modulation of both ionotropic and metabotropic post-synaptic
receptors through Zn2+-speciﬁc binding sites [144,145]. In patho-
logical conditions free Zn2+ accumulates intracellularly and leads to
neurotoxicity [146]. Zn2+ is a critical endogenous modulator of
NMDAR activity. Synaptic Zn2+, acts on both a high afﬁnity voltage-
independent site present on the GluN2A subunit [147,148], as well as
on a low afﬁnity, voltage-dependent site on the NR2B subunit [149],
and is a potent inhibitor of NMDAR-mediated currents [150]. On the
other hand, Zn2+ is also able to enhance NMDAR currents through an
indirect mechanism that involves Src kinase activation [151]. While, in
physiological conditions, Zn2+ exposure has multiple modulatory ef-
fects relevant to normal signaling functions, prolonged exposure or
higher concentration can trigger brain cell death,more easily in neurons
than astrocytes [152,153]. Zn2+-induced neuronal death depends on
excessive Zn2+ inﬂux across the plasma membrane via several routes,
including voltage- and agonist-gated Ca2+ channels as well as the
Na+-Ca2+ exchanger [154].In ALS the role of free Zn2+ as a neuromodulator of the
glutamatergic system and ultimately as a neurotoxic agent has been
somehow overlooked. Yao [155] demonstrated that prolonged
kainate-induced Zn2+ exposure increases 4-hydroxynanonenal, a
major membrane lipid peroxidation product, and decreases GLT-1
production, essentially via the AMPAR. We have investigated the
modulatory effects that a brief exposure to extracellular Zn2+ has on
NMDAR-mediated neurotoxicity in cortical cultures carrying the
G93A mutation [156]. Results from our study indicate that: (1) mixed
neuronal/glial cortical cultures are less sensitive than near-pure neu-
ronal cultures to Zn2+/NMDAR-mediated toxicity; (2) Zn2+ pre-
treatment enhances NMDAR-mediated toxicity, particularly in G93A
neurons; (3) this enhanced Zn2+/NMDAR-induced neuronal death
is likely mediated by intracellular overload of Ca2+ and increased
ROS generation. These results ﬁt nicely with the role played by the
glutamate-driven ROS production in ALS and with the role of Zn2+ it-
self as a potent mitochondrial toxin [146]. It is quite possible that the
proven capability of Zn2+ to interfere with mitochondrial function
may be enhanced in organelles that are made more vulnerable to the
damaging effects of both Ca2+ and Zn2+ because of the expression of
SOD1 mutations [157,158]. These ﬁndings warrant further investiga-
tions on the largely unexplored role of synaptic free Zn2+ and its mod-
ulatory role on NMDARs in promoting ALS-related neuronal loss.
6. Polyamines
Polyamines, such as spermine and spermidine, are amines widely
distributed throughout the body [159] (Fig. 5). They are present in
the intracellular space where they regulate several cellular functions.
In the CNS they can be released into the extracellularmilieu, upon syn-
aptic activity, and modulate neuronal ﬁring by acting on various ion
channels and receptors, including the NMDAR [160]. They are the
ﬁrst discovered and best characterized positive allosteric modulators
of the receptor. Polyamines, in particular spermine, have multiple ef-
fects on NMDAR function, including an enhancement of the NMDA re-
ceptor currents and a voltage-dependent pore block [161,162]. It
seems that these two effects of spermine involve at least two discrete
spermine-binding sites on NMDA receptors. Polyamine potentiation is
largely observed in the GluN1/GluN2 combination [163,164]. It seems
that polyamines selectively potentiates this subtype of NMDAR by
modulating the proton sensor, thus attenuating the inhibition by
protons at physiological pH [165]. De Vera et al. [166] demonstrated,
using human cortical cell cultures, that spermine toxicity was pre-
vented by MK801, a noncompetitive NMDAR antagonist, and by
ifenprodil, an antagonist of the polyamine site on the NMDAR. Thus
spermine induces cell death via a necrotic pathway when associated
with the NMDAR.
Polyamine levels have been measured in ALS patients and animal
models. Spermine and spermidine, are increased in the red blood cells
of patients with ALS [167], and in the ventral horn region of female
ALS patients but not in male [168]. Putresceine levels were increased
in the G93A mouse, along with an increased catalytic activity of the
polyamine pathway key enzyme ornithine decarboxylase [169]. The
signiﬁcance of these ﬁndings is unclear and apparently not a general
characteristic of the ALS pathology. However, it is possible to hypoth-
esize that in an extracellular environment abnormally enriched with
polyamines the NMDAR function will be enhanced, thus emphasizing
excitotoxic cell death.
7. Conclusions
ALS is a neurodegenerative disease with a complex pathophysiol-
ogy. Glutamatergic excitotoxicity has received much attention as a
critical player in ALS development and progression. Every aspect of
the glutamatergic transmission, including neurotransmitter release
and uptake, as well as receptor dependent functions has been linked
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Fig. 5. Polyamine degradation pathway. Arginine, an intermediate in the urea cycle, is a precursor of the polyamines via ornithine. The enzyme ornithine decarboxylase (ODC) gen-
erates putrescine and is the ﬁrst rate-limiting step in polyamine biosynthesis. An aminopropyl group, derived from the decarboxylation of S-adenosylmethionine, is then added to
putresceine to form spermidine and then spermine, by the spermidine and spermine synthases.
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excitotoxic path leading to ALS has been so far neglected. The scope
of the present review is to call attention to the studies that have re-
vealed how some of the most important endogenous modulators of
the NMDARs are modiﬁed in ALS, and how they may interfere with
the ALS pathophysiology. In this context pharmacological treatments
with memantine, a low-afﬁnity, non-competitive NMDAR antagonist,
have shown promising results in the ALS mouse model [170,171]
The outcome of two memantine trials in ALS patients have been pub-
lished [172,173] and in both trials the drug resulted safe and well
tolerated by patients. Chang and colleagues. (22nd International Sym-
posium on ALSA/MND Abstract Book, Sydney, Australia, 2011) have
reported that memantine treatment (10 mg) is effective in slowing
spinal MN loss in ALS patients under Riluzole treatment. This ﬁnding
has supported the planning of a large Phase 3 trial to verify whether
memantine alone or in combination with other drugs, can exert im-
portant therapeutic effects in ALS patients.
Thus, it is intriguing to hypothesize that regain control of the
NMDAR functionality will in turn affect AMPAR function, due to the
close interaction between these receptors, thereby further hampering
the ALS-related excitotoxic drive.
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